Targeted Topical Endobronchial Therapy

Improved means of treating tracheobronchitis, bronchiectasis and pneumonia in patients

Ventilator-associated pneumonia is reported to be the most common hospital-acquired infection among patients requiring mechanical ventilation. It is well-known to treat such infections with systemically administered antibiotics, but simultaneous treatment of the whole body with multiple antibiotic agents is fraught with complications ranging from accelerating the antibiotic-resistant strains disrupting fluid and electrolyte balance and compromising the antiviral defense mechanisms of mucosal epithelia throughout the body. Systemically administered antibiotics can also have adverse effects on the liver, kidney and skeleton. Such concerns have resulted in a recent call for a de-escalating strategy for antibiotic administration.

Dr. Gerald Smaldone, Professor of Medicine, Physiology and Biophysics at Stony Brook University invented a means of antibiotic delivery in mechanically ventilated patients as primary or adjunctive treatment for respiratory infection. The method generally comprises administering to an animal subject or human patient in need thereof, as an aerosol, a therapeutically effective amount of an antibiotic substance or a pharmaceutically acceptable salt thereof. Several antibiotics may be delivered in combination according to the invention or one by one in sequence.

Targeted delivery of antibiotics to the lung Minimize toxic side effects Defines the presence of infection Insures delivery of appropriate levels of antibiotics

Delivery of antibiotics to the lung

PCT publication No. WO 2004/071368

Product in phase III

Exclusive License - All Fields

Aerosol delivery Tracheobronchitis Nosocomial pnemonia 

Patent Information:
Technology/Start-up ID: